Expert Point of View: Sharon H. Giordano, MD, MPH

Get Permission

Sharon H. Giordano, MD, MPH

Formal discussant Sharon H. Giordano, MD, MPH, Professor of Medicine and Chair of Health Services Research at The University of Texas MD Anderson Cancer Center, Houston, emphasized how important it is to preserve fertility in these younger patients with breast cancer.

“The main downside is an increase in menopausal symptoms during treatment,” she said.

Because of the missing data on 38% of participants, low accrual rates, and early termination of the trial, Dr. Giordano could not consider these results definitive.

“Having said that, I would be comfortable offering this option to my young patients who desire fertility preservation,” Dr. Giordano stated. ■

Disclosure: Dr. Giordano reported no potential conflicts of interest.

Related Articles

Goserelin With Chemotherapy Prevents Early Menopause, Helps Preserve Fertility in Younger Women With Hormone Receptor–Negative Breast Cancer

The good news for younger women with hormone receptor–negative early breast cancer is that adding goserelin (Zoladex), a luteinizing hormone–releasing hormone (LHRH) agonist, to chemotherapy can prevent sudden menopause, better preserve ovarian function and fertility, and lead to successful...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.